The purification challenge behind engineered antibody drugs for cancer
This article explores the complex science and engineering behind purifying pharmaceutical molecules at industrial scale, focusing on bispecific antibodies — engineered molecules that can target cancer cells and immune cells simultaneously. It highlights the challenges of manufacturing these sophisticated biologics, where many promising molecules fail not due to efficacy but because of purification difficulties. The piece emphasizes the importance of understanding a molecule's manufacturing liabilities early in development, drawing on insights from global life science company Cytiva about the critical role of purification science in bringing innovative medicines to patients.
Key quotes
With one of its molecular arms, the engineered antibody seizes a cancer cell and with the other, an immune cell called a killer T cell.
Many clinically relevant molecules fall by the wayside because of the complex challenge of purifying them at industrial scale.
That's why understanding a molecule's manufacturing liabilities early on is crucial.
From the article
You might also wanna read
BPI Asia Digital Series
Manufacturing and regulatory hurdles threaten cell and gene therapy progress
The article discusses how manufacturing and regulatory challenges are hindering the progress of cell and gene therapies, particularly in can
medium.com·25d ago
How excessive FDA manufacturing requirements are bottlenecking cell and gene therapy companies
The article argues that excessive FDA manufacturing requirements are crippling cell and gene therapy companies, using Grace Therapeutics as
writingruxandrabio.com·5d ago
Engineered antibodies enhance complement-mediated immune clearance against drug-resistant bacterial infections
Researchers engineered monoclonal antibodies (mAbs) that bypass the initial steps of the classical complement activation pathway, enhancing
science.org·21d ago
Advancing Monoclonal Antibody Manufacturing Through Integrate Process Intensification
Molecular glue approach doubles survival time for pancreatic cancer patients in breakthrough trial
Chemical biologist Gregory Verdine developed a novel approach to fighting cancer by using "molecular glues" to bind disease-causing proteins
pasadenastarnews.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.